{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.3113","value":"73.726"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"description":"%BRtrough is the percent inhibition for Rtrough. Crossover C2D1 visit was combined with C2D1 visit for the analysis of this endpoint.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study. Participants who experienced disease progression and received placebo were allowed to cross over to receive AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle.","id":"OG000","title":"Randomization Phase AG-120 Plus Cross Over Phase AG-120"}],"paramType":"MEAN","populationDescription":"PD Analysis Population consisted of all participants who were enrolled and received any dose of study medication (AG-120) with sufficient plasma sample data to assess pharmacodynamic parameters. Number analyzed is the number of participants with data available for analyses at the specified time point.","reportingStatus":"POSTED","timeFrame":"Post-dose Cycle 2 Day 1 (each cycle = 28 days)","title":"Plasma 2-hydroxyglutarate (2-HG) Levels of AG-120: %BRtrough","type":"SECONDARY","unitOfMeasure":"percent"}